01 June 2005 : Original article
Use of recombinant human activated protein C in treatment of severe sepsis in a pregnant patient with fully symptomatic ovarian hyperstimulation syndrome
Małgorzata Mikaszewska-Sokolewicz, Ewa Mayzner-ZawadzkaMed Sci Monit 2005; 11(6): CS27-32 :: ID: 16511
Abstract
Summary
Background: Severe sepsis during pregnancy is a life-threatening condition for the mother, due to multiorgan failure and uncontrolled infl ammatory response. It is associated with high risk of death for the fetus.
Case Report: The paper presents the course and treatment of severe iatrogenic sepsis in a patient in very early pregnancy. The sepsis was a result of complications after overstimulation of the ovaries in the
course of treatment of infertility. The risk of the patient’s death, assessed in the Intensive Care Unit according to APACHE II and SAPS II scores was 73%, whereas indirect assessment of the embryo
in the 3[sup]rd[/sup] week of pregnancy, based on determination of serum gestational hormone levels was ambiguous, but rather unfavorable. The patient’s condition improved considerably after intensive treatment, including, among others, the use of activated protein C (APC). After the completion of treatment, in the 5[sup]th[/sup] week of pregnancy, the gestational hormone levels increased to the values appropriate for such fetal age. The development of pregnancy was also confi rmed by ultrasonography.
Conclusions: The paper presents a case of severe sepsis in the course of ovarian hyperstimulation syndrome, not described in the literature so far, as well as the fi rst successful administration of activated protein C in 21-day pregnancy.
Keywords: Ovarian Hyperstimulation Syndrome - drug therapy, Ovarian Hyperstimulation Syndrome - physiopathology, Pregnancy Complications, Infectious - drug therapy, Pregnancy Complications, Infectious - physiopathology, APACHE, Cardiac Output, Heart Rate, Ovarian Hyperstimulation Syndrome - physiopathology, Platelet Count, Pregnancy, Pregnancy Complications, Infectious - physiopathology, Protein C - therapeutic use, Recombinant Proteins - therapeutic use, Sepsis - etiology, Stroke Volume
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952